Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta

Circulation Research

Volumn 79, Issue 4, 1996, Pages 794-801

  Bacon, Caragh R ^a   Cary, Nathaniel R B ^b   Davenport, Anthony P ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

atherosclerosis; endothelin; endothelin A; endothelin B; human artery

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR; RECEPTOR SUBTYPE;

AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0029820628     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.79.4.794     Document Type: Article

References (51)

1. Ohlstein EH, Douglas SA. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Dev Res. 1993;29:108-128.
2. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
3. De Nucci G, Thomas R, D'Orleans-Juste P, Antumes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988;85:9797-9800.
4. Harrison VJ, Randriantsoa A, Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992;105:511-513.
5. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992;13:103-108.
6. Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol. 1993;110:1201-1205.
7. Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol. 1996;117:986-992.
8. Bacon CR, Gary NRB, Davenport AP. Distribution of endothelin receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 1995;26(suppl 3):S439-S441.
9. A receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995;115:191-197.
10. Kurihara H, Yoshizumi M, Sugiyama T, Yamaoki K, Nagai R, Takaku F, Satoh H, Inui J, Yanagisawa M, Masaki T, Yazaki Y. The possible role of endothelin-1 in the pathogenesis of vasospasm. J Cardiovasc Pharmacol. 1989;13(suppl 5):S132-S137.
11. Yang Z, Richard V, von Segesser L, Bauer E, Stultz P, Turina M, Luscher TF. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation. 1990;82:188-195.
12. Chester AH, O'Neil GS, Allen SP, Luu TN, Tadjkarimi S, Yacoub MH. Effect of endothelin on normal and diseased human coronary arteries. Eur J Clin Invest. 1992;22:210-213.
13. Gibbons GH, Dzau VJ. The emerging concept of vascular remodelling. N Engl J Med. 1994;330:1431-1438.
14. Weissberg PL, Witchell C, Davenport AP, Hesketh TR, Metcalf JC. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis. 1990;85:257-262.
15. Douglas SA, Louden C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Elliott JD, Ohlstein EH. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty: protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res. 1994;75:190-197.
16. Maemura K, Kurihara H, Morita T, Ohhashi Y, Yazaki Y. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology. 1992;38:29-35.
17. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172:1741-1748.
18. Martin-Nizard F, Houssaini HS, Lestavel-Delattre S, Duriez P, Fruchard J-C. Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett. 1991; 293:127-130.
19. Boulanger CM, Tanner FC, Bea M-L, Hahn AWA, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-1197.
20. Resink TJ, Hahn AWA, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun. 1990;168:1303-1310.
21. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
22. Takahashi K, Ghatei MA, Lam H-C, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in diabetes mellitus. Diabetologia. 1990; 33:306-310.
23. Bath PM, Martin JF. Serum platelet-derived growth factor and endothelin concentrations in human hypercholesterolaemia. J Intern Med. 1991;230:313-317.
24. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metab Clin Exp. 1994;43:267-269.
25. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 1995;91:941-947.
26. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun. 1993;191:1081-1088.
27. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP. Expression of endothelin peptides and mRNA in human heart. Clin Sci. 1996;90:37-46.
28. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992;10:1379-1386.
29. Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Davenport AP. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993;72:526-538.
30. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for the characterization of ligand binding systems. Anal Biochem. 1980;107:220-239.
31. A receptors. Br J Pharmacol. 1994;111:4-6.
32. B) receptors. Life Sci. 1992;51:47-52.
33. Davenport AP, Beresford IJM, Hall MD, Hill RG, Hughes J. Quantitative autoradiography in neuroscience. In: Van Leeuwen FW, Buijis RM, Pool CW, Pach O, eds. Molecular Neuroanatomy. Amsterdam, Netherlands: Elsevier Science Publishing Co; 1988;3:121-145.
34. Barger AC, Beeuwkes R, Lainey LL, Silverman KJ. Hypothesis: vaso vasorum and neovascularization of human coronary arteries: a possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984;310:175-177.
35. Mugge A, Lopez JAG, Heistad DD, Lichtlen PR. Vasoconstriction in response to activated leukocytes: implications for vasospasm. Eur Heart J. 1993;14(suppl I):87-92.
36. Krum H, Itescu S. Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects. Clin Exp Pharmacol Physiol. 1994;21:311-313.
37. Opgaard OS, Adner M, Gulbenkian S, Edvinsson L. Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins. J Cardiovasc Pharmacol. 1994;23:576-583.
38. Elshourbagy NA, Korman DR, Wu HL, Sylvester DR, Lee JA, Nuthalaganti P, Bergsma DJ, Kumar CS, Nambi P. Molecular characterization and regulation of the human endothelin receptors. J Biol Chem. 1993;268:3873-3879.
39. Azuma H, Hamasaki H, Niimi Y, Terada T, Matsubara O. Role of endothelin-1 in neointima formation after endothelial removal in rabbit carotid arteries. Am J Physiol. 1994;267:H2259-H2267.
40. Eguchi S, Hirata Y, Imai T, Kanno K, Marumo F. Phenotypic change of endothelin receptor subtype in cultured rat vascular smooth muscle cells. Endocrinology. 1994;134:222-228.
41. Power RF, Wharton J, Zhao Y, Bloom SR, Polak JM. Autoradiographic localization of endothelin-1 binding sites in the cardiovascular and respiratory systems. J Cardiovasc Pharmacol. 1989;13 (suppl 5):S50-S56.
42. Hasegawa K, Fujiwara H, Doyama K, Inada T, Ohtani S, Fujiwara T, Hosoda K, Nakao K, Shigetake S. Endothelin-1-selective receptor in the arterial intima of patients with hypertension. Hypertension. 1994;23:288-293.
43. Kanse SM, Wijelath E, Kanthou C, Newman P, Kakkar VV. The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. Lab Invest. 1995;72:376-382.
44. Serradeil-Le Gal C, Herbert JM, Garcia C, Boutin M, Maffrand JP. Importance of the phenotypic state of vascular smooth muscle cells on the binding and the mitogenic activity of endothelin. Peptides. 1991;12:575-579.
45. 2+ mobilization through its specific receptors in murine peritoneal macrophages. FEBS Lett. 1991;280:103-106.
46. Helset E, Sildnes T, Seljelid R, Konopski ZS. Endothelin-1 stimulates human monocytes in vitro to release TNF-alpha, IL-1beta and IL-6. Mediat Inflammation. 1993;2:417-422.
47. Helset E, Sildnes T, Konopski ZS. Endothelin-1 stimulates monocytes in vitro to release chemotactic activity identified as interleukin-8 and monocyte chemotactic protein-1. Mediat Inflammation. 1994; 3:155-160.
48. Magazine HI, Andersen TT, Bruner CA, Malik AB. Vascular contractile potency of endothelin-1 is increased in the presence of monocytes or macrophages. Am J Physiol. 1994;266(Heart Circ Physiol 35):H1620-H1625.
49. 125I]ET-1 binding to the atherosclerotic human coronary artery. Br J Pharmacol. 1994;112:386-389.
50. A subtype. Br J Pharmacol. 1995;114:1110-1116.
51. Shiosaki K. Endothelin receptor antagonists. Exp Opin Ther Patents. 1994;4:1361-1365.